A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).

ESMO Open · 2024 · PMC11402031 · PMID 39214049

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

24 , 25 , 26 In this study, concomitant TP53 mutations with MET alterations showed a trend toward poor PFS and OS in patients treated with tepotinib.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.